One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Aura Biosciences, Inc.
AURA · NGM · Healthcare · Biotechnology
Current price
$6.34
52-week range
$4.73 - $9.54
Market cap
$657.49M
Balance sheet
Healthy
-17.01x Concerning
Net cash $307.25M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Aura Biosciences, Inc.
Aura Biosciences is developing a new kind of cancer treatment that uses special particles to deliver drugs directly to solid tumors. Their main focus right now is on a treatment called bel-sar, which is being tested for eye cancer and is also showing promise for bladder cancer. This matters because if bel-sar is successful, it could offer a new way to fight these difficult diseases, potentially leading to better patient outcomes.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-15.61M
FY2024 Q4
$-24.25M
FY2025 Q1
$-23.54M
FY2025 Q2
$-20.81M
FY2025 Q3
$-20.19M
FY2025 Q4
$-20.64M
FY2026 Q1
$-30.00M
FY2026 Q2
$-32.52M
Revenue
—
Net income
$-45.64M
Diluted EPS
-0.48
Operating cash flow
$-32.50M
Free cash flow
$-32.52M
Fetching…
Sources
Revenue
—
Net income
$-33.69M
Diluted EPS
-0.50
Operating cash flow
$-29.89M
Free cash flow
$-30.00M
Fetching…
Sources
Revenue
—
Net income
$-25.56M
Diluted EPS
-0.34
Operating cash flow
$-20.47M
Free cash flow
$-20.64M
Fetching…
Sources
Revenue
—
Net income
$-26.13M
Diluted EPS
-0.40
Operating cash flow
$-20.14M
Free cash flow
$-20.19M
Fetching…
Sources
Revenue
—
Net income
$-27.02M
Diluted EPS
-0.47
Operating cash flow
$-20.77M
Free cash flow
$-20.81M
Fetching…
Sources
Revenue
—
Net income
$-27.48M
Diluted EPS
-0.55
Operating cash flow
$-23.36M
Free cash flow
$-23.54M
Fetching…
Sources
Revenue
—
Net income
$-25.83M
Diluted EPS
-0.52
Operating cash flow
$-23.95M
Free cash flow
$-24.25M
Fetching…
Sources
Revenue
—
Net income
$-21.04M
Diluted EPS
-0.42
Operating cash flow
$-15.27M
Free cash flow
$-15.61M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $6.34
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $307.2M - more cash than debt. Interest coverage -17.0x.
Net debt
$-307.25M
Interest coverage
-17.01x
Aura Biosciences, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
AURA
BASELINE
Aura Biosciences, Inc.
Total debt $16.59M Interest coverage -17.01x This is the baseline the peer rows are being compared against.
Total debt $1.04M Interest coverage -15.06x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $247.36M Interest coverage -8.77x Neither company has much profit cushion over interest right now.
Total debt $73.41M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $26.25B Interest coverage 11.43x This peer still has a real interest-payment cushion, while AURA does not.
What you should know
The case for and against AURA
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -53.5% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-3.12x
P/B
2.08x
P/S
—
EV/EBITDA
-2.56x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-53.5%
ROA
-31.2%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
16.82x
Quick ratio
16.65x
Total debt
$16.59M
Total cash
$323.84M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.75
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-103.01M
Free CF TTM
$-85.19M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—